Welcome to our dedicated page for EyePoint SEC filings (Ticker: EYPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The EyePoint, Inc. (EYPT) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, offering detailed insight into this clinical-stage biopharmaceutical company focused on serious retinal diseases. EyePoint’s filings, including multiple Form 8-K reports, document material events such as clinical milestones, equity offerings, and corporate actions related to its lead investigational product, DURAVYU™ (vorolanib intravitreal insert).
Through these filings, investors can review clinical development updates formally reported to the SEC, such as the completion of enrollment in the pivotal Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration, positive recommendations from the independent Data Safety Monitoring Committee, and the announcement of a pivotal Phase 3 program in diabetic macular edema (COMO and CAPRI). Filings also reference the posting of investor presentations that summarize estimated cash and investments and outline EyePoint’s development plans.
EyePoint’s SEC documents further detail capital markets activity, including an underwriting agreement and public offering of common stock and pre-funded warrants, as well as a Controlled Equity Offering Sales Agreement for at-the-market issuances. These filings describe the terms of offerings, net proceeds, intended use of funds to advance DURAVYU in wet AMD and DME, and the legal opinions related to the validity of issued securities.
Additional filings cover corporate governance and compensation matters, such as amendments to the 2023 Long-Term Incentive Plan, inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4), and the results of stockholder votes at the annual meeting. Risk factors and forward-looking statement sections referenced in filings highlight regulatory interactions, including an FDA warning letter pertaining to EyePoint’s Watertown manufacturing facility and an August 2022 subpoena from the U.S. Attorney’s Office for the District of Massachusetts.
On Stock Titan, EyePoint’s SEC filings are paired with AI-powered summaries that help explain the significance of each document, from 8-K current reports to registration-related filings. This allows readers to quickly understand how new offerings, clinical disclosures, or governance changes may relate to EyePoint’s development of DURAVYU and its broader ophthalmic pipeline, while still having direct access to the full text of each filing as made available through EDGAR.
EyePoint Pharmaceuticals filed a prospectus supplement covering the registered offering of up to $200,000,000 of common stock pursuant to its Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. The supplement relates to the company’s effective Form S-3 (File No. 333-290867), which became automatically effective upon filing.
The company also filed a legal opinion from Hogan Lovells US LLP validating the Shares, included as Exhibit 5.1. This filing provides a framework to sell shares as needed under the existing sales agreement, offering flexibility to access capital subject to market conditions.
EyePoint Pharmaceuticals (EYPT) launched an at-the-market offering of up to $200,000,000 in common stock under a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald. Shares may be sold from time to time in transactions deemed “at the market offerings” under Rule 415(a)(4), including sales on The Nasdaq Global Market. Cantor will act as sales agent and receive a fixed commission equal to 3.0% of the aggregate gross sales price per share sold.
The company states it intends to use net proceeds to advance clinical development of DURAVYU for wet AMD and DME, support earlier-stage pipeline programs leveraging its Durasert E technology, and for general corporate purposes. The common stock trades on Nasdaq under “EYPT”; the last reported sale price was $12.45 on November 3, 2025.
EyePoint Pharmaceuticals (EYPT) reported a wider Q3 loss as it advances late‑stage trials. Total revenue was $0.97 million, down 91% year over year, mainly due to prior deferral recognition tied to YUTIQ® licensing. Research and development rose to $47.8 million (up 62%) as Phase 3 wet AMD studies (LUGANO, LUCIA) continued. Net loss was $59.7 million, or $0.85 per share.
Cash, cash equivalents and marketable securities were $204.0 million as of September 30, 2025. After quarter‑end, the company closed an underwritten equity offering with net proceeds of approximately $162.1 million and sold additional shares via its ATM. Management states these resources are expected to fund operations into the fourth quarter of 2027, beyond anticipated 2026 topline data for DURAVYU™.
Deferred revenue from the ANI YUTIQ® arrangement was fully recognized by Q2 2025, reducing current‑period license revenue. The company recorded a $4.7 million accrual for a potential DOJ matter resolution. Shares outstanding were 82,787,220 as of October 30, 2025.
EyePoint Pharmaceuticals (EYPT)Exhibit 99.1.
This is a routine disclosure that makes the quarter’s results available through the attached exhibit. EYPT’s common stock trades on the Nasdaq Global Market under the symbol EYPT.
EyePoint Pharmaceuticals completed an underwritten public offering of 11,000,000 shares of common stock at $12.00 per share and pre-funded warrants to purchase 1,500,000 shares at $11.999 per warrant. The company also granted the underwriters a 30‑day option to purchase up to an additional 1,875,000 shares at the same price.
The company received approximately $141 million in net proceeds after underwriting discounts and commissions, and the offering closed on October 16, 2025. EyePoint plans to use the proceeds to advance clinical development of DURAVYU for wet age‑related macular degeneration and diabetic macular edema, support earlier‑stage pipeline initiatives, and for general corporate purposes.
The pre‑funded warrants are exercisable at any time, do not expire, carry a $0.001 per share exercise price, and include beneficial ownership limits of 4.99% or 9.99% at the holder’s election, adjustable up to 19.99% with 61 days’ notice.
EyePoint Pharmaceuticals launched a primary offering of 11,000,000 shares of common stock and pre-funded warrants for 1,500,000 shares at $12.00 per share and $11.999 per warrant.
The deal is expected to generate approximately $140.7 million in net proceeds, with a 30-day option for underwriters to purchase up to 1,875,000 additional shares. Management plans to use the funds to advance Phase 3 development of DURAVYU for wet AMD and DME, support earlier-stage programs, and for general corporate purposes. The company states these resources, together with existing cash, are expected to fund operations into the fourth quarter of 2027, beyond anticipated wet AMD topline data in 2026.
The pre-funded warrants carry a $0.001 exercise price and may be exercised for shares; there will be no public market for these warrants.
EyePoint Pharmaceuticals (EYPT) launched a primary offering of $150,000,000 of common stock via a prospectus supplement, with underwriters granted a 30‑day option to purchase up to an additional $22,500,000 at the public offering price, less underwriting discounts and commissions.
The company’s common stock trades on Nasdaq Global Market under “EYPT.” Estimated net proceeds are intended to advance clinical development of DURAVYU for wet AMD and DME, support earlier-stage pipeline programs, and for general corporate purposes. EyePoint estimated approximately $200 million in cash, cash equivalents and marketable securities as of September 30, 2025. The company states that existing cash plus expected net proceeds should fund operations into the fourth quarter of 2027.
Recent updates note DURAVYU’s Phase 3 program initiation planning in DME and ongoing Phase 3 trials in wet AMD. As context, shares outstanding were 68,889,649 as of June 30, 2025, plus 825,844 shares issued under an at‑the‑market program through October 6, 2025. A 60‑day lock‑up applies to the company and insiders, with specified exceptions.
EyePoint Pharmaceuticals (EYPT) filed an 8-K noting two updates. The company posted an investor presentation that includes estimated cash and investments as of September 30, 2025. These figures were calculated before review by the independent registered public accounting firm and are subject to change upon completion of the quarterly report for the period ended September 30, 2025.
EyePoint also announced details for its pivotal Phase 3 program evaluating DURAVYU (vorolanib intravitreal insert) for diabetic macular edema, with first patient dosing anticipated in Q1 2026. The press release and presentation were made available on the company’s website.
EyePoint Pharmaceuticals (EYPT) Chief Financial Officer George Elston reported transfers of company common stock on September 19, 2025. The filing shows 20,000 shares were disposed of from Mr. Elston's direct holdings and the same number were recorded as held indirectly in an irrevocable family trust for the benefit of his children, with JP Morgan Trust Company of Delaware as trustee. After the reported transactions, Mr. Elston's direct beneficial ownership is reported as 62,114 shares and the Family Trust holds 20,000 shares. The filing also notes 1,266 shares were acquired on July 31, 2025 under EyePoint’s 2019 Employee Stock Purchase Plan. The reporting attorney-in-fact signed the form on September 22, 2025.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 6,800,000 shares of EyePoint Pharmaceuticals common stock, representing 9.88% of the company based on 68,811,736 shares outstanding. The filing states the reporting persons hold shared voting and shared dispositive power over the shares and report no sole voting or dispositive power. Adage is identified as the investment manager of the entity that directly holds the shares. The reporting persons certify these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.